17Apr 2017
A pre-clinical (in-vivo & in-vitro) study report from Holy Stone Healthcare's novel targeting anti-cancer drug in colorectal cancer, CA102N, is published on《Nanomedicine》, volume 2017:12 on March 27, 2017.
read more
13Apr 2017
Dr. Eskouhie Tchaparian, from our Preclinical & Development Division, participated in the AACR Annual Meeting 2017 on April 1 - 5, 2017 at Walter E. Washington Convention Center, Washington, D.C., USA.
read more
30May 2016
Holy Stone Healthcare, together with representatives of Holy Stone Biotech & MDT Int’l, will be exhibiting at 2016 BIO International Convention in USA. The event will be held from June 7th – 9th at Moscone Center, San Francisco.
read more

Vision & Mission

We are committed to developing lifesaving therapeutics and targeted delivery technologies to improve the quality of life of patients worldwide. Our mission is to create innovative therapeutic products based on hyaluronic acid using our know-how and experience to address unmet clinical needs with superior tolerability and efficacy.


We are focused on development of new drugs and medical devices, especially hyaluronic acid related therapeutic products.